SCHEMBL10249407

SCHEMBL10249407

CCn1c(-c2ccc(NS(=O)(=O)C3CC3)cc2)c(N)c2ccc(OCc3cccnc3)cc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 4/20 0.42
PRMT1 Q99873 1/20 0.40
PRMT8 Q9NR22 1/20 0.40
SGK1 O00141 1/20 0.37
MAOA P21397 1/20 0.37
DYRK1A Q13627 1/20 0.37
PRKDC P78527 1/20 0.36
ADAMTS4 O75173 1/20 0.36
CTPS1 P17812 2/20 0.36
PDE5A O76074 2/20 0.35
PDE4A P27815 2/20 0.35
PDE4B Q07343 2/20 0.35
PDE4C Q08493 2/20 0.35
PDE4D Q08499 2/20 0.35
TYK2 P29597 1/20 0.35
ADAM17 P78536 1/20 0.35
PIK3CD O00329 1/20 0.35
BRD4 O60885 1/20 0.34
CREBBP Q92793 1/20 0.34
IDO1 P14902 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10097679 0.90 AR (0.44) MAOADYRK1APRKDCADAMTS4PDE5A
SCHEMBL10095837 0.89 PRMT6 (0.39) PRMT6PRMT1PRMT8MAOADYRK1A
SCHEMBL10097698 0.84 AR (0.41) PRMT6SGK1DYRK1APDE5A
SCHEMBL13152186 0.82 KDM4E (0.43) PRMT6PRMT1PRMT8SGK1DYRK1A
SCHEMBL13152607 0.82 SGK1 (0.39) PRMT6PRMT1PRMT8SGK1CTPS1
SCHEMBL13152372 0.81 SGK1 (0.43) PRMT6PRMT1PRMT8SGK1IDO1
SCHEMBL13152319 0.81 GRM2 (0.45) MAOADYRK1APRKDCADAMTS4ADAM17
SCHEMBL13151918 0.80 SGK1 (0.39) PRMT6SGK1CTPS1
SCHEMBL10097622 0.80 KMT2A (0.43) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL13152661 0.79 SGK1 (0.40) PRMT6PRMT1PRMT8SGK1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2012-01-12 US disclosed
WO-2010118009-A1 HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS PTC THERAPEUTICS, INC. (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C OAT, HAVCR2, HCCS PRMT6 1297/4885PRMT1 1692/4885PRMT8 1868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.